SCNX

Scienture Holdings, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$2.9

Price (1 Year)

$15.25 $2.88

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %55.5 / %30
Non-compliant assets / Total market cap %57.1 / %30
Non-compliant revenue / Total income %44.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.

Website

Analysis (Turkish): SCNX Hissesi Caiz mi, Helal mi? Scienture Holdings, Inc. Katılım Analizi